{"id":"W4318754961","doi":"10.1016/j.euo.2023.01.010","title":"Survival by Depth of Response and Efficacy by International Metastatic Renal Cell Carcinoma Database Consortium Subgroup with Lenvatinib Plus Pembrolizumab Versus Sunitinib in Advanced Renal Cell Carcinoma: Analysis of the Phase 3 Randomized CLEAR Study","year":2023,"lang":"en","type":"article","venue":"European Urology Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":34,"is_retracted":false,"has_abstract":true,"ca_institutions":"Western University","funders":"National Cancer Institute; Eisai Incorporated; Genentech; Ipsen; Astellas Pharma; EUSA Pharma; Seagen; Sanofi; Exelixis; Memorial Sloan-Kettering Cancer Center; Merck Sharp and Dohme; Ono Pharmaceutical; Eisai; Merck KGaA; Handok; Bristol-Myers Squibb; AstraZeneca; Amgen; Pfizer","keywords":"Medicine; Lenvatinib; Sunitinib; Pembrolizumab; Renal cell carcinoma; Internal medicine; Oncology; Everolimus; Subgroup analysis; Kidney cancer; Response Evaluation Criteria in Solid Tumors; Clinical trial; Cancer; Phases of clinical research; Meta-analysis; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.007761072,0.0007141267,0.002046835,0.0003961497,0.0002503655,0.0007045037,0.001033166,0.0007701038,0.001353309],"category_scores_gemma":[0.003512737,0.0003237277,0.004090301,0.0004688601,0.000488865,0.0006463791,0.0007588757,0.001668267,0.0001567906],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008830501,"about_ca_system_score_gemma":0.001297323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009656947,"about_ca_topic_score_gemma":0.00262448,"domain_scores_codex":[0.9958636,0.003045061,0.000180105,0.0004035894,0.0003423889,0.000165322],"domain_scores_gemma":[0.9968105,0.0009445021,0.0009946756,0.0003812399,0.0001608429,0.0007081233],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.915854,0.00224866,0.05463419,0.000437152,0.01025623,0.00006211366,0.0001089511,0.001558036,0.003505806,0.0001553499,0.001059218,0.01012037],"study_design_scores_gemma":[0.4428263,0.1561783,0.3729932,0.0001316921,0.01378104,0.0002881572,0.0002042128,0.006620509,0.003106542,0.0007613222,0.002996127,0.0001125518],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9956241,0.001770939,0.0003152622,0.0001941582,0.00003180691,0.0006347269,0.001041254,0.00001627834,0.0003714828],"genre_scores_gemma":[0.995684,0.0003429988,0.0006457987,0.0002482926,0.00006663802,0.0009008041,0.001824731,0.00001016639,0.0002766129],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007761072,"threshold_uncertainty_score":0.04104501,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03463152331413209,"score_gpt":0.3178959216777795,"score_spread":0.2832643983636474,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}